Home Search
Abstracts		 Browse
Oral Sessions		 Browse
Poster Sessions		 Program
Committee		 Visit
WebSite		 Contact
Us

 

Session 33  Oral Abstracts
Late Breaking Phase III Trials of New Antiretrovirals
Tuesday, 6:30 - 7:10 pm
Room: West Hall B

Moderators:
  John Coffin
  Tufts Univ, Boston, MA, US and NCI-Frederick, MD, US

  Christopher Aiken
  Vanderbilt Univ Sch of Med, Nashville, TN, US
6:30 pm  104aLB Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic, ART-experienced Patients Infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-Week Results
M Nelson1, G Fätkenheuer2, I Konourina3, A Lazzarin4, N Clumeck5, A Horban6, M Tawadrous7, J Sullivan3, H Mayer7, and Elna van der Ryst*3
1Chelsea and Westminster Hosp, London, UK; 2Universitaetsklinik Köln, Germany; 3Pfizer Global R&D, Sandwich, UK; 4Hosp San Raffaele, Milan, Italy; 5Ctr Hosp Univ St Pierre, Brussels, Belgium; 6Szpital Zakazny Centrum Diagnostyki i Terapii AIDS, Warsaw, Poland; and 7Pfizer Global R&D, New London, CT, US
  104bLB Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic ART-experienced Patients Infected with CCR5-tropic HIV-1: 24-Week Results of a Phase 2b/3 Study in the US and Canada
J Lalezari1, J Goodrich2, E DeJesus3, H Lampiris4, R Gulick5, M Saag6, C Ridgway7, M McHale7, E van der Ryst7, and Howard Mayer*2
1Quest Clin Res, Univ of California, San Francisco, US; 2Pfizer Global R&D, New London, CT, US; 3Orlando Immunology Ctr, FL, US; 4San Francisco VAMC, Univ of California, US; 5Weill Med Coll of Cornell Univ, New York, NY, US; 6Univ of Alabama at Birmingham, US; and 7Pfizer Global R&D, Sandwich, UK
6:50 pm  105aLB Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus
David Cooper*1, J Gatell2, J Rockstroh3, C Katlama4, P Yeni5, A Lazzarin6, J Chen7, R Isaacs7, H Teppler7, B Nguyen7, and for the BENCHMRK-1 Study Group
1Univ of New South Wales, Sydney, Australia; 2Univ of Barcelona, Spain; 3Univ of Bonn, Germany; 4Hosp Pitie Salpetriere, Paris, France; 5Hosp Bichat Claude Bernard, Paris, France; 6San Raffaele Sci Inst, Milan, Italy; and 7Merck Res Labs, West Point, PA, US
  105bLB Results of BENCHMRK-2, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus
Ron Steigbigel*1, P Kumar2, J Eron3, M Schechter4, M Markowitz5, M Loufty6, J Zhao7, R Isaacs7, B Nguyen7, H Teppler7, and for the BENCHMRK-2 Study Group
1State Univ of New York at Stony Brook, US; 2Georgetown Univ Med Ctr, Washington, DC, US; 3Univ of North Carolina at Chapel Hill, US; 4Federal Univ of Rio de Janeiro, Brazil; 5Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US; 6Canadian Immunodeficiency Res Collaborative, Toronto; and 7Merck Res Labs, West Point, PA, US
7:10 pm      106 Update on the CONRAD Cellulose Sulfate Trial
G Doncel and L van Damme
CONRAD, Arlington, VA, US